<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00585468</url>
  </required_header>
  <id_info>
    <org_study_id>15121</org_study_id>
    <secondary_id>Award# CERL080AUS33</secondary_id>
    <nct_id>NCT00585468</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State</brief_title>
  <official_title>Pharmacokinetic Profile of Myfortic (Enteric Coated Mycophenolate Sodium) in a Rapid Steroid Withdrawal Protocol in Combination With Tacrolimus in Stable Renal Transplant Recipients in the Fed and Fasting State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Literature regarding the effect of food on the pharmacokinetic (PK) profile of enteric-coated
      mycophenolate sodium combined with tacrolimus and corticosteroid withdrawal is lacking. The
      objective of this study is to identify pharmacokinetic variables of mycophenolate sodium
      (Myfortic®) in the fed and fasting state in stable renal transplant patients on tacrolimus in
      combination with a rapid steroid withdrawal protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mycophenolate sodium (Myfortic®) is an antiproliferative immunosuppressant used in renal
      transplantation. Mycophenolate sodium is formulated as an enteric coated tablet that releases
      mycophenolic acid (MPA) which in turn inhibits inosine monophosphate dehydrogenase (IMPDH).
      Through inhibition of IMPDH, the de novo pathway of purine synthesis, which T and B
      lymphocytes rely on for proliferation, is blocked. The pharmacokinetic profile of
      mycophenolate sodium has mainly been studied in combination with cyclosporine and steroids.
      There is little information on the pharmacokinetics of mycophenolate sodium in combination
      with tacrolimus and currently no published information in steroid withdrawal. All current
      published data on the pharmacokinetics of MPA have been in patients receiving chronic
      corticosteroids as part of their immunosuppression regimen. As immunosuppression
      minimization, and especially corticosteroid withdrawal, become more popular it is important
      to understand how mycophenolate sodium and its metabolites behave in a two-drug maintenance
      immunosuppression regimen. The study will assess the pharmacokinetic profile of mycophenolate
      sodium in patients on tacrolimus dose adjusted based on levels, and a steroid withdrawal
      protocol.

      Renal transplant patients will act as their own controls in a randomized crossover design
      with pharmacokinetic profiles occurring at two different time points. Immunosuppression will
      consist of induction therapy with maintenance immunosuppression consisting of tacrolimus plus
      mycophenolate sodium. Corticosteroids will be withdrawn per institutional protocol within the
      first week post transplant.

      Approximately 3-4 weeks post transplant, patients that met enrollment criteria and have
      consented to participate in the study will be instructed to take 720 milligrams of
      mycophenolate sodium orally twice daily for one week either separated from food by two hours
      (fasting state) or with a meal (fed state). After one week, patients will be admitted for
      approximately 24 hours where they will continue to receive mycophenolate sodium with or
      without food. During this period, blood samples will be drawn at 0, 1, 2, 3, 4, 5, 6, 7, 8,
      9, 10, 11 and 12 hours following the dose to evaluate levels of mycophenolic acid (MPA) and
      mycophenolic acid glucuronide (MPAG). After 24 hours, patients will be discharged with
      instructions to take mycophenolate sodium in the opposite manner (fed or fasting state) than
      they had the week before. At the end of the second week the patients will return for a second
      PK evaluation with blood collection at the same time points following mycophenolate sodium
      dosing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Mycophenolic Acid (MPA)</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum Observed Plasma Concentration (Cmin) of Mycophenolic Acid (MPA)</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Mycophenolic Acid (MPA)</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) From Time Zero to 12 Hours Post-Dose [AUC (0-12)] of Mycophenolic Acid (MPA)</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose</time_frame>
    <description>AUC (0-12) = Area under the plasma concentration versus time curve from time zero (pre-dose) to 12 hours post-dose, measured in microgram-hours per milliliter (mcg*h/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Mycophenolic Acid Glucuronide (MPAG)</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum Observed Plasma Concentration (Cmin) of Mycophenolic Acid Glucuronide (MPAG)</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Mycophenolic Acid Glucuronide (MPAG)</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to 12 Hours Post-Dose [AUC (0-12)] of Mycophenolic Acid Glucuronide (MPAG)</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose</time_frame>
    <description>AUC (0-12) = Area under the plasma concentration versus time curve from time zero (pre-dose) to 12 hours post-dose, measured in microgram-hours per milliliter (mcg*h/mL)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Myfortic - Fed State</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mycophenolate sodium taken with a meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myfortic - Fasting State</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mycophenolate sodium taken separately from food by 2 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myfortic</intervention_name>
    <description>Myfortic 720 mg orally twice daily</description>
    <arm_group_label>Myfortic - Fed State</arm_group_label>
    <arm_group_label>Myfortic - Fasting State</arm_group_label>
    <other_name>mycophenolate sodium</other_name>
    <other_name>mycophenolic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal transplant recipients greater than 18 years of age, who have given written
             consent

        Exclusion Criteria:

          -  Taking medications that may alter the metabolism of tacrolimus or mycophenolate sodium

          -  Experienced an acute rejection episode prior to the pharmacokinetic profile collection

          -  Serum creatinine &gt;2 mg/dL

          -  Neutropenia (Absolute Neutrophil Count &lt; 1.3x10^3/mL)

          -  Received a previous transplant other than a kidney

          -  Receiving chronic steroids at time of transplant

          -  Known hypersensitivity to tacrolimus, mycophenolate mofetil, mycophenolate sodium,
             mycophenolic acid or any of its excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fuad Shihab, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Utah-Solid Organ Transplant</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Arns W, Breuer S, Choudhury S, Taccard G, Lee J, Binder V, Roettele J, Schmouder R. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant. 2005 Apr;19(2):199-206.</citation>
    <PMID>15740555</PMID>
  </reference>
  <reference>
    <citation>Kaplan B, Meier-Kriesche HU, Minnick P, Bastien MC, Sechaud R, Yeh CM, Balez S, Picard F, Schmouder R. Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. Clin Transplant. 2005 Aug;19(4):551-8.</citation>
    <PMID>16008604</PMID>
  </reference>
  <reference>
    <citation>Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol. 1997 Sep;5(3):225-32.</citation>
    <PMID>9402690</PMID>
  </reference>
  <reference>
    <citation>van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001 Apr;23(2):119-28.</citation>
    <PMID>11294511</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2008</study_first_posted>
  <results_first_submitted>September 10, 2013</results_first_submitted>
  <results_first_submitted_qc>April 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 6, 2016</results_first_posted>
  <last_update_submitted>April 1, 2016</last_update_submitted>
  <last_update_submitted_qc>April 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fed State First, Then Fasting State</title>
          <description>720 milligrams (mg) mycophenolate sodium orally twice daily with a meal for one week in the first intervention period, followed by one week of 720 mg mycophenolate sodium orally twice daily separated by food by 2 hours in the second intervention period.</description>
        </group>
        <group group_id="P2">
          <title>Fasting State First, Then Fed State</title>
          <description>720 mg mycophenolate sodium orally twice daily separated from food by 2 hours for one week in the first intervention period, followed by one week of 720 mg mycophenolate sodium orally twice daily with a meal in the second intervention period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes groups randomized to the Fed State first and to the Fasted State first</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.6" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of Mycophenolic Acid (MPA)</title>
        <time_frame>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Myfortic - Fed State</title>
            <description>Mycophenolate sodium taken with a meal</description>
          </group>
          <group group_id="O2">
            <title>Myfortic - Fasting State</title>
            <description>Mycophenolate sodium taken separately from food by 2 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of Mycophenolic Acid (MPA)</title>
          <units>micrograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="6.7"/>
                    <measurement group_id="O2" value="18.7" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0163</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minimum Observed Plasma Concentration (Cmin) of Mycophenolic Acid (MPA)</title>
        <time_frame>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Myfortic - Fed State</title>
            <description>Mycophenolate sodium taken with a meal.
Myfortic: Myfortic 720 mg orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Myfortic - Fasting State</title>
            <description>Mycophenolate sodium taken separately from food by 2 hours.
Myfortic: Myfortic 720 mg orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Observed Plasma Concentration (Cmin) of Mycophenolic Acid (MPA)</title>
          <units>micrograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.6"/>
                    <measurement group_id="O2" value="1.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Mycophenolic Acid (MPA)</title>
        <time_frame>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Myfortic - Fed State</title>
            <description>Mycophenolate sodium taken with a meal.
Myfortic: Myfortic 720 mg orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Myfortic - Fasting State</title>
            <description>Mycophenolate sodium taken separately from food by 2 hours.
Myfortic: Myfortic 720 mg orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Mycophenolic Acid (MPA)</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) From Time Zero to 12 Hours Post-Dose [AUC (0-12)] of Mycophenolic Acid (MPA)</title>
        <description>AUC (0-12) = Area under the plasma concentration versus time curve from time zero (pre-dose) to 12 hours post-dose, measured in microgram-hours per milliliter (mcg*h/mL)</description>
        <time_frame>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Myfortic - Fed State</title>
            <description>Mycophenolate sodium taken with a meal.
Myfortic: Myfortic 720 mg orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Myfortic - Fasting State</title>
            <description>Mycophenolate sodium taken separately from food by 2 hours.
Myfortic: Myfortic 720 mg orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) From Time Zero to 12 Hours Post-Dose [AUC (0-12)] of Mycophenolic Acid (MPA)</title>
          <description>AUC (0-12) = Area under the plasma concentration versus time curve from time zero (pre-dose) to 12 hours post-dose, measured in microgram-hours per milliliter (mcg*h/mL)</description>
          <units>mcg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5" spread="15.2"/>
                    <measurement group_id="O2" value="63.9" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.146</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of Mycophenolic Acid Glucuronide (MPAG)</title>
        <time_frame>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Myfortic - Fed State</title>
            <description>Mycophenolate sodium taken with a meal.
Myfortic: Myfortic 720 mg orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Myfortic - Fasting State</title>
            <description>Mycophenolate sodium taken separately from food by 2 hours.
Myfortic: Myfortic 720 mg orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of Mycophenolic Acid Glucuronide (MPAG)</title>
          <units>micrograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.9" spread="35.7"/>
                    <measurement group_id="O2" value="113.0" spread="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4937</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minimum Observed Plasma Concentration (Cmin) of Mycophenolic Acid Glucuronide (MPAG)</title>
        <time_frame>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Myfortic - Fed State</title>
            <description>Mycophenolate sodium taken with a meal.
Myfortic: Myfortic 720 mg orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Myfortic - Fasting State</title>
            <description>Mycophenolate sodium taken separately from food by 2 hours.
Myfortic: Myfortic 720 mg orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Observed Plasma Concentration (Cmin) of Mycophenolic Acid Glucuronide (MPAG)</title>
          <units>micrograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4" spread="24.9"/>
                    <measurement group_id="O2" value="57.0" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9669</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Mycophenolic Acid Glucuronide (MPAG)</title>
        <time_frame>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Myfortic - Fed State</title>
            <description>Mycophenolate sodium taken with a meal.
Myfortic: Myfortic 720 mg orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Myfortic - Fasting State</title>
            <description>Mycophenolate sodium taken separately from food by 2 hours.
Myfortic: Myfortic 720 mg orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax) of Mycophenolic Acid Glucuronide (MPAG)</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="11"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to 12 Hours Post-Dose [AUC (0-12)] of Mycophenolic Acid Glucuronide (MPAG)</title>
        <description>AUC (0-12) = Area under the plasma concentration versus time curve from time zero (pre-dose) to 12 hours post-dose, measured in microgram-hours per milliliter (mcg*h/mL)</description>
        <time_frame>0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Myfortic - Fed State</title>
            <description>Mycophenolate sodium taken with a meal.
Myfortic: Myfortic 720 mg orally twice daily</description>
          </group>
          <group group_id="O2">
            <title>Myfortic - Fasting State</title>
            <description>Mycophenolate sodium taken separately from food by 2 hours.
Myfortic: Myfortic 720 mg orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to 12 Hours Post-Dose [AUC (0-12)] of Mycophenolic Acid Glucuronide (MPAG)</title>
          <description>AUC (0-12) = Area under the plasma concentration versus time curve from time zero (pre-dose) to 12 hours post-dose, measured in microgram-hours per milliliter (mcg*h/mL)</description>
          <units>mcg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="967.5" spread="364.0"/>
                    <measurement group_id="O2" value="962.2" spread="289.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9607</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were not collected in this study</desc>
      <group_list>
        <group group_id="E1">
          <title>Myfortic - Fed State</title>
          <description>Mycophenolate sodium taken with a meal</description>
        </group>
        <group group_id="E2">
          <title>Myfortic - Fasting State</title>
          <description>Mycophenolate sodium taken separately from food by 2 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Fuad Shihab, MD</name_or_title>
      <organization>University of Utah</organization>
      <phone>801-585-3823</phone>
      <email>fuad.shihab@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

